Welcome to the e-CCO Library!

P394: Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Sorokina Alexdóttir, M.(1);Bourgonje, A.R.(2);Asser Karsdal, M.(1);Bay-Jensen, A.C.(1);Faber, K.N.(2);Loveikyte, R.(2);van Dullemen, H.M.(2);Visschedijk, M.C.(2);Festen, E.A.M.(2);K. Weersma, R.(2);Dijkstra, G.(2);Mortensen, J.H.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P395 Management of pouch vaginal fistulae in ulcerative colitis: A 35-year experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. REZA1, E. Van Praag2, N. Iqbal1, C. Twum-Barima1, A. Hart3,4, S. Clark5,6, P. Tozer1,6

Created: Thursday, 30 January 2020, 10:12 AM
P395: Dermatological reactions associated with anti–TNF therapy in inflammatory bowel disease- an 12 year experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Bhandare*, R. Diyar, J. Taylor, J.K. Limdi

Created: Thursday, 21 February 2019, 9:14 AM
P395: Etrolizumab demonstrated no difference among doses in symptomatic and endoscopic-based evaluation of remission in anti-TNF-α-naïve patients in a post-hoc analysis of the phase 2 ulcerative colitis trial (EUCALYPTUS)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.J.1, Schreiber S.2, Tang M.T.3, Tatro A.R.3, Oh Y.S.*3, Maciuca R.3

Created: Wednesday, 20 February 2019, 10:36 AM
P395: Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn’s disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Pai, R.(1);De Hertogh, G.(2);Reinisch, W.(3);Harpaz, N.(4);Feagan, B.(5);Agada, N.(6);Pollack, P.(6);Chan, L.S.(6);Protic, M.(6);Magro, F.(7);
Created: Wednesday, 2 June 2021, 4:12 PM
P395: Postoperative immunosuppressive therapies decrease the risk of second intestinal surgery in patients with Crohn’s disease: a retrospective cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

Y. Nagata*1,2, M. Esaki3, Y. Fuyuno2, Y. Okamoto2, S. Fujioka2, A. Hirano2, J. Umeno2, T. Torisu2, T. Moriyama2, S. Nakamura1, T. Kitazono2

Created: Friday, 22 February 2019, 9:41 AM
P395: Proactive Therapeutic Drug Monitoring May Reduce the Need for Combination Therapy in Inflammatory Bowel Disease Patients Treated with Infliximab
Year: 2022
Source: ECCO'22
Authors: Doherty, J.(1);Varley, R.(2);Dunne, C.(2);Mc Carthy, F.(1);Hartery, K.(1);Mc Kiernan , S.(1);Kevans, D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P395: Real-life prospective experience with adalimumab in ulcerative colitis in Italy: preliminary results of a pilot study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Daperno*1, A. Armuzzi2, D. Pugliese2, A. Lavagna1, P. Gionchetti3, F. Rizzello3

Created: Friday, 22 February 2019, 9:49 AM
P395: Short-term clinical efficacy and safety of teduglutide for Crohn's disease patients with short bowel syndrome
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kaku, K.(1)*;Sato, T.(1);Takeuchi, J.(2);Uchino , M.(3);Fujihira, Y.(1); Shimizu, K.(1);Yokoyama, K.(1);Yagi , S.(1);Takashima, Y.(1);Ikenouchi, M.(1);Kojima, K.(1);Kawai, M.(1); Nagase , K.(1);Kamikozuru, K.(1);Yokoyama , Y.(1);Takagawa, T.(1); Ikeuchi, H.(3);Watanabe, K.(1);Shinzaki , S.(1);
Created: Friday, 14 July 2023, 11:05 AM
P396 Pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C.A. Lee1, L. Acevedo1, D.A. Oh1, P. Baweja1, K. Gilder1, D. Han2, S. Jhee2, K. Komori1, S. Mullin1, T. Nguyen-Cleary1, K. Schmelzer2, Y. Tang1, J. Zhang1, J. Grundy1

Created: Thursday, 30 January 2020, 10:12 AM
P396: Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with Inflammatory Bowel Disease in a real-life setting
Year: 2021
Source: ECCO'21 Virtual
Authors: De Somer, T.(1);Deprez, N.(2);Baert, D.(1);Deceuninck, M.(3);Huys, I.(1);Mattens, V.(4);Sterckx, A.(4);Vanden Branden, S.(4);Vanderstraeten , E.(1);Vandervoort , J.(4);Van Heddegem, N.(1);Dewint, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P396: COVID-19 pandemic-related endoscopy delays did not translate to deleterious outcomes for patients with Inflammatory Bowel Disease: A retrospective cohort study
Year: 2022
Source: ECCO'22
Authors: Chambers, J.(1);Gurpreet, M.(1);Maria, M.(1);Reena, K.(1);Aze Suzanne, W.(1);
Created: Friday, 11 February 2022, 3:52 PM
P396: Cyclosporin A efficacy in a paediatric ulcerative colitis: a retrospective single-centre study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Osiecki*, M. Dadalski, J. Kierkus

Created: Friday, 22 February 2019, 9:49 AM
P396: Long-term efficacy of thiopurines as maintenance treatment in 130 patients with ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lefevre C., Fotsing G., Wangermez M., Beau P.

Created: Wednesday, 20 February 2019, 10:36 AM
P396: Monitoring adalimumab compliance using smart sharp bin technology
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Hazel*1, C. Smyth1, O. Kelly1, R. J. Farrell1

Created: Friday, 22 February 2019, 9:41 AM
P396: Pharmacokinetics, immunogenicity and clinical outcomes of golimumab from the PURSUIT PEDS ulcerative colitis study long-term (through week 126) extension
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Hyams1, C.D. O’Brien2, L. Padgett2, J. Rosh3, D. Turner4, G. Veereman5, A. Griffiths6, M.B. Heyman7, G. Wahbeh8, J. Adedokun2, R. Strauss2, D. Chan2, J. Lynch2*

Created: Thursday, 21 February 2019, 9:14 AM
P396: Ustekinumab Is A Promising Option For The Treatment Of Postoperative Recurrence Of Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Macaluso, F.S.(1)*;Grova, M.(1);Mocciaro, F.(2);Di Mitri, R.(2);Privitera, A.C.(3);Distefano, M.E.(3);Vitello, A.(4);Camilleri, S.(4);Ferracane, C.(5);Pluchino, D.(5);Belluardo, N.(6);Giangreco, E.(6);Fries, W.(7);Viola, A.(7);Cappello, M.(8);Amato, L.(8);Bertolami, C.(9);Ventimiglia, M.(10);Renna, S.(1);Casà, A.(1);De Vivo, S.(1);Orlando, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P397 Surveillance in ulcerative colitis: Can we predict the risk for intraepithelial neoplasia?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Estorninho1, P. Freire2, S. Lopes1, M. Ferreira1, M. Ferreira1, F. Portela1, P. Figueiredo1

Created: Thursday, 30 January 2020, 10:12 AM
P397: Advanced therapy persistence and need for dose optimisation in a cohort of Inflammatory Bowel Disease patients in Argentina: a real-world evidence multicenter study (REMAR study)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lasa, J.(1)*;Nazario, E.(2);Zubiaurre, I.(2);Rausch, A.(2);Hermida, R.(3);Cassella, F.(4);Marzullo, S.(4);Suarez Pellegrino, A.(5);Deborah, B.(5);Toro, M.(5);Novillo, A.(6);Omodeo, J.(6);Tirado, P.(7);Bellicoso, M.(7);Olivera, P.(8);Balderramo, D.(9);Torello, R.(9);Chiaraviglio, L.(9);Scacchi, A.(3);Linares, M.(10);Gonzalez, R.(11);Bentolila, F.(11);Lubrano, P.(12);Quintero, O.(10);De Paula, J.(13);Gonzalez Sueyro, R.(13);Sanchez, B.(13);Fuxman, C.(14);Velazquez , A.(15);
Created: Friday, 14 July 2023, 11:05 AM
P397: Approach and management of psychological aspects of inflammatory bowel disease described by patients and physicians in Spain. The ENMENTE Project
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Marín-Jiménez I.*1, Panadero A.2, Gobbo Montoya M.3, Cañas M.4, Modino Y.5, Guardiola J.6, Cea-Calvo L.7, Juliá B.7, Romero C.7, Carmona L.8, Barreiro-de Acosta M.9

Created: Wednesday, 20 February 2019, 10:36 AM